Premarket roundup: Amgen, NetSuite

Among the premarket activity stories for Tuesday, Sept. 16, from AP Financial News:

NEW YORK (AP) _ Biotechnology company Amgen Inc. will release anticipated study results on its osteoporosis drug candidate denosumab shortly Tuesday morning, giving investors and analysts a clearer outlook on whether the treatment is a potential blockbuster.

NEW YORK (AP) _ A Piper Jaffray analyst upgraded NetSuite Inc., which delivers business management software over the Web, on Tuesday, saying the company's revenue growth will likely accelerate in the third quarter.

NEW YORK (AP) _ Shares of Eli Lilly & Co. are trading around their lowest prices in 11 years, and a JPMorgan analyst downgraded the stock Tuesday, pointing to the impending generic competition for some of the company's top-selling drugs.

NEW YORK (AP) _ An analyst upgraded shares of Chubb Corp. and Travelers Cos. on Tuesday, saying the property and casualty insurers stand to gain from the troubles at rival American International Group Inc.

NEW YORK (AP) _ Despite massive damage from successive hurricanes, Entergy Corp.'s credit ratings were left unchanged by Standard & Poor's.

NEW YORK (AP) _ Shares of packaging company MeadWestvaco Corp. could see increased activity Tuesday after an analyst said its shares are trading at a "substantial discount."